Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

• Published in: The New England journal of medicine Vol. 381; no. 26; pp. 2506 - 2518
• Main Authors: de Wit, Ronald, de Bono, Johann, Sternberg, Cora N, Fizazi, Karim, Tombal, Bertrand, Wülfing, Christian, Kramer, Gero, Eymard, Jean-Christophe, Bamias, Aristotelis, Carles, Joan, Iacovelli, Roberto, Melichar, Bohuslav, Sverrisdóttir, Ásgerður, Theodore, Christine, Feyerabend, Susan, Helissey, Carole, Ozatilgan, Ayse, Geffriaud-Ricouard, Christine, Castellano, Daniel
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 26.12.2019
• Subjects: Aged; Aged, 80 and over; Analgesics; Androgen Antagonists - administration & dosage; Androgen Antagonists - adverse effects; Androgens; Androstenes - administration & dosage; Androstenes - adverse effects; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Cancer therapies; Castration; Colony-stimulating factor; Death; Granulocyte colony-stimulating factor; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Leukocytes (granulocytic); Male; Metastases; Metastasis; Middle Aged; Pain; Patients; Phenylthiohydantoin - administration & dosage; Phenylthiohydantoin - adverse effects; Phenylthiohydantoin - analogs & derivatives; Prednisone; Prednisone - administration & dosage; Progression-Free Survival; Prostate cancer; Prostate-specific antigen; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Safety; Survival; Taxoids - administration & dosage; Taxoids - adverse effects; Working groups

A randomized trial involving patients with metastatic prostate cancer whose disease progressed after receipt of docetaxel and hormonal therapy showed that cabazitaxel was superior to an androgen-signaling–targeted agent in extending imaging-based progression-free survival, overall survival, and PSA...